Ben Stevens
Ben is the editor of Business of Cannabis. Since 2021, he has researched, written, and published the vast majority of the outlet’s content, delivering agenda-setting journalism on regulation, business strategy, and policy across Europe.
Ben Stevens · page 141
- Pharmaceutical
European Cannabis Stocks Review: OCT Announces ‘Budget Review’ As Finance Director Quits, Tikun Olam Cannbit Receives EU GMP & More From IIROC
AFTER a month of relatively positive upwards trajectory for many European cannabis stocks, this week has seen a return to stagnation and decline, although a number of companies have managed to retain their price gains.
- Pharmaceutical
New Data Suggests NHS Licenced Cannabis-Based Medicine Prescriptions Are On The Rise This Year
NEW UK government data suggest that the number of NHS prescriptions for ‘licenced’ cannabis-based medicines could rise significantly this year.
- Press releases
Stenocare Enters Its 4th Market Starting Sales In Australia In Q4 2022
AFTER securing market access and approvals in both Denmark, Sweden and UK, STENOCARE A/S (“Stenocare”) now takes a first and firm footstep into the southern hemisphere entering Australia.
- Companies
Juicy Fields Has Now Entered Its Next Phase As More Fraudsters Emerge ‘Attracted By The Business Opportunity Of Scamming These Victims’
SIX weeks after the initial downfall of Juicy Fields, and the scandal has entered a new, unexpected phase that threatens to be just as harmful as the first.
- Markets & Stocks
Goodbody Health Announces 1:10 Share Consolidation As It Completes Redomiciliation To Guernsey
GOODBODY Health informed investors this week that it intends to apply a 1:10 ‘reverse stock split’ as it waits for its shares to return to trading on the Aquis Stock Exchange.
- Companies
JuicyFields: The World’s Biggest Cannabis Scam Explained – Smells Like Business Podcast
IN JULY, cannabis crowdfunding company Juicy Fields collapsed overnight without explanation, leaving what is thought to be over 100,000 investors unable to access their funds.
- Markets & Stocks
European Cannabis Stocks Review: Chill Brands Becomes Latest UK-Listed Stock To Stage Comeback, IM Cannabis Edges Closer To Delisting, & More From Cellular Goods
THIS week has seen European cannabis stocks once again gain momentum in the face of dismal economic news.
- News
InterCure Continues Record Run But Faces Looming Supply Issues In Home Market
INTERCURE has continued its run of record results, seeing both revenues and profits skyrocket year-on-year during the second quarter of 2022, marking its tenth consecutive quarter of profitable growth.
- News
Columbia Care To ‘Wind Down’ Operations In UK & Europe
COLUMBIA Care has confirmed to BusinessCann that it is set to ‘wind down’ its operations across the UK and Europe as its upcoming $2bn takeover by Cresco Labs nears its final stages.
- News
Cannabis Companies With ESG Principles At Their Heart Are Now ‘The Ones That Are More Investable’
AS Tory leadership hopefuls continue their scramble to launch policies aimed at softening the blow of the looming cost-of-living crisis, Environmental, Social and Governance (ESG) initiatives are seemingly falling rapidly out of favour.
- Adult-Use
Switzerland Has ‘Laid The Groundwork For Its Medical Cannabis Industry To Flourish’ And Could Soon Be Exporting ‘Very High-Quality Flower’
LAST week Switzerland became the latest in a string of European countries to relax its restrictive access to medical cannabis for both patients and businesses.
- Pharmaceutical
European Cannabis Stocks Review: LSE-Listed Cannabis Stocks Enjoy Unexpected Comeback As Cellular Goods Jumps 40%
In further signs of positive momentum, UK listed cannabis stocks made an unexpected comeback this week, following months of unrelenting share price losses across Europe.












